Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 39.7% on Tuesday . The company traded as high as GBX 7.14 ($0.09) and last traded at GBX 5.50 ($0.07). 53,455,387 shares traded hands during mid-day trading, an increase of 148% from the average session volume of 21,559,516 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The firm has a market capitalization of £24.49 million, a price-to-earnings ratio of -588.00 and a beta of 1.53. The business has a fifty day moving average price of GBX 1.83 and a two-hundred day moving average price of GBX 1.75.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- The Risks of Owning Bonds
- Sizing Up a New Opportunity for NVIDIA Investors
- What Are Treasury Bonds?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
